NMD Pharma Reports Results from the ESTABLISH Study - an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New leading gene therapy company created combining late-stage X-linked retinitis pigmentosa program from AGTC, a preclinical program spun out from the University of Oxford and a second. | June 12, 2023
ZUG, Switzerland, May 3, 2023 - MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today
ZUG, Switzerland, April 19, 2023 - MoonLake Immunotherapeutics AG ("MoonLake"; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases,